Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aladote (PP100-01) + NAC in Paracetamol Overdose
NCT03177395Phase 1Completed
- Sponsor
- Egetis Therapeutics
- Start
- Jun 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of calmangafodipir in paracetamol poisoning, sponsored by Egetis Therapeutics. Primary endpoint: Safety Events at 90 days. Started Jun 2017; status: completed.
02
Drugs
calmangafodipir
03
Conditions
paracetamol poisoning
Beyond the preview
Go deeper on NCT03177395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03177395.